

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Takeshi IMANISHI et al. Patentee

Patent No. 7,217,805

Issued May 15, 2007

Serial No. 10/054,300

Filed January 22, 2002

BICYCLONUCLEOSIDE ANALOGUES For

Docket No. : 01834CIP/HG

Confirm No. : 5360

Customer No.: 01933

#### REQUEST FOR CERTIFICATE OF CORRECTION UNDER 37 CFR 1.322

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

#### SIR:

APRO 1 2000 It is respectfully requested that a Certificate of Correction, as per the attached Form PTO/SB/44, be granted. The errors are Patent Office printing errors.

This request is to correct the SEQUENCE LISTING, in Column 63 of the patent, by deleting "<160> NUMBER OF SEQ ID NOS:9" and inserting in place thereof items <120>, <130>, <140>, <141>, <150>, <151>, <160> and <170>, as per the attached Form PTO/SB/44.

With respect to the aforesaid correction to the SEQUENCE LISTING in Column 63 of the patent, see the enclosed copy of page

CERTIFICATE OF MAILING

I hereby certify this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class mail in an envelope addressed to:

Commissioner for Patents.

P.O. Box 1450

Alexandria, VA 22313-1450 on the date noted below.

Attorney: Richard S. Barth

Dated: March 23, 2009

In the event that this Paper is late filed, and the necessary petition for extension of time is not filed concurrently herewith, please consider this as a Petition for the requisite extension of time, and to the extent not tendered by payment attached hereto, authorization to charge the extension fee. or any other fee required in connection with this Paper, to Account No. 06-1378.

1 of the SEQUENCE LISTING filed on April 1, 2004, wherein said items <120>, <130>, <140>, <141>, <150>, <151>, <160> and <170> are listed in their entirety.

Respectfully submitted

Richard S. Barth

Reg. No. 28,180

Favorable action on this Request for a Certificate of Correction is respectfully requested.

Frishauf, Holtz, Goodman & Chick, P.C.
220 Fifth Avenue, 16th Fl.
New York, NY 10001-7708
Tel. Nos. (212) 319-4900

(212) 319-4551/Ext. 219 Fax No.: (212) 319-5101

E-Mail Address: BARTH@FHGC-LAW.COM

RSB/ddf

Encs.: (1) Form PTO/SB/44 (in duplicate)

(2) copy of page 1 of the SEQUENCE LISTING filed on April 1, 2004

-2-

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. (Also Form PTO-1050)

#### UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

Page \_ 1 \_ of \_ 1

PATENT NO.

: 7,217,805

APPLICATION NO.: 10/054,300

**ISSUE DATE** 

: May 15, 2007

INVENTOR(S)

<sup>1</sup> Takeshi IMANISHI et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 63, middle of page after SEQUENCE LISTING, delete

"<160> NUMBER OF SEQ ID NOS:9";

Column 63, middle of the page, after SEQUENCE LISTING, insert

--<110> Imanishi, Takeshi

Obika, Satoshi

<120> Novel Bicyclonucleoside Analogues

<130> 01834CIP/HG

<140> US 10/054,300

<141> 2002-01-22

<150> JP HEI 11-207170

<151> 1999-07-22

<160>9

<170> PatentIn version 3.1--

MAILING ADDRESS OF SENDER (Please do not use customer number below):

FRISHAUF, HOLTZ, GOODMAN & CHICK, P.C. 220 Fifth Avenue, 16th Floor, New York, New York 10001-7088

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

(Also Form PTO-1050)

## UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

		Page <u>1</u> of <u>1</u>	1
PATENT NO.	: <b>7,217,805</b>	<u> </u>	_

APPLICATION NO.: 10/054,300

ISSUE DATE : May 15, 2007

INVENTOR(S) : Takeshi IMANISHI et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 63, middle of page after SEQUENCE LISTING, delete

"<160> NUMBER OF SEQ ID NOS:9";

Column 63, middle of the page, after SEQUENCE LISTING, insert

--<110> Imanishi, Takeshi

Obika, Satoshi

<120> Novel Bicyclonucleoside Analogues

<130> 01834CIP/HG

<140> US 10/054,300

<141> 2002-01-22

<150> JP HEI 11-207170

<151> 1999-07-22


<160>9

<170> PatentIn version 3.1--

MAILING ADDRESS OF SENDER (Please do not use customer number below):

FRISHAUF, HOLTZ, GOODMAN & CHICK, P.C. 220 Fifth Avenue, 16th Floor, New York, New York 10001-7088

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



### MAR 2 7 2009

# PRADENA!

OIPE

<110> Imanishi, Takeshi Obika, Satoshi

<120> Novel Bicyclonucleoside Analogues

<130> 01834CIP/HG

<140> US 10/054, 300

(141) 2002-01-22

JP HEI11-207170

<150> JP HEI11-20 <151> 1999-07-22

<160> 9

<170> Patentin version 3.1

<210> <211> <212> <213>

12

DNA

Artificial

<220>

Description of Artificial Sequence: Synthesized oligonucleotide (223) for testing the nuclease resistance

<221> <222> <223> modified\_base

- (11) modified uridine

<400> 1 ttttttttt nt

12

<210> <211> <212> <213> 15

DNA Artificial

<220>
<223> Description of Artificial Sequence: Synthesized oligonucleotide for testing the formability of a triple strand

<220>
<221> modified\_base
<222> (6)

<223> 5-methyl 2'-deoxycytidine

<220>

modified\_base

⟨221⟩ ⟨222⟩

3'-amino-3'-deoxy-2'-0, 4'-C-methylene-5-methyluridine

<220>

modified\_base

〈221〉 〈222〉 (10)

5-methyl 2'-deoxycytidine (223)

(220)

<221><222> modified\_base

(12)

5-methyl 2'-deoxycytidine <223>

<220>

(221) modified\_base

(222) (14)

(223) 5-methyl 2'-deoxycytidine

**<400> 2** 

tttttntntn tntnt

<210>

⟨211⟩ 21 ⟨212⟩ DNA

15